ISCHEMIA REPERFUSION INJURY THERAPEUTICS MARKET ANALYSIS
Global Ischemia Reperfusion Injury Therapeutics Market: Key Developments
In March 2022, SBI Pharmaceuticals, a pharmaceutical company in collaboration with the University of Oxford, announced that SBI Pharmaceuticals had initiated a phase II clinical trial to develop a cardio protective agent combining 5-ALA hydrochloride and the cardiac surgery under cardiopulmonary bypass, the sodium ferrous citrate is response for the mitigation of ischemia reperfusion.
In April 2021, PharmaDrug Inc., a specialty pharmaceutical company, announced that U.S. FDA (Food and Drug Administration) had granted Orphan Drug Designation to dimethyltryptamine (DMT) for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation, which includes the liver, kidney, heart, and lung.
Ischemia Reperfusion Injury Therapeutics Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :